Perioperative Treatment With Tranexamic Acid in Melanoma
Status:
Not yet recruiting
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
Surgery is a key element in the treatment of melanoma, and naturally linked with an
inflammatory response and recruitment of innate immune cells. Although surgery has a
favorable intent, surgery-induced inflammation, neutrophils in particular, may accelerate
growth of local and systemic micrometastases. Thus, improving cancer surgery and modulating
the wound microenvironment in ways that benefit the patients is crucial.
Repurposing already approved drugs in a cancer setting has gained increasing interest in
recent years. Interestingly, tranexamic acid was recently suggested as an anti-cancer drug,
capable of reducing tumor growth in experimental animal models and reducing the viability of
different melanoma cell lines.
As a novel approach, sponsor and investigators will conduct a Randomised Clinical Trial,
using perioperative treatment with Tranexamic Acid, aiming to prevent the early relapses for
patients with melanoma.